加载中
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
常规交易时段
US$13.7447
−US$0.0853 · -0.62%
盘中时间采用ET。市场数据可能有所延迟。
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
日内区间
当前US$13.7447
52周区间
当前US$13.7447
盘中时间采用ET。市场数据可能有所延迟。
Kardigan, Inc. is a clinical-stage precision therapeutics company, which engages in developing medicines that target the root cause of specific cardiovascular diseases where no approved treatments exist. It combines clinical-stage drug programs with artificial intelligence, real-world patient data, and analytics through its “Cardiac Intelligence” platform to accelerate research and improve treatment outcomes. The company was founded by Tassos E. Gianakakos, Jay Edelberg, Bob McDowell, Leslie Leinwand, and Elizabeth McNally in August 2023 and is headquartered in Princeton, NJ.
日内区间
当前US$13.7447
52周区间
当前US$13.7447
| 项目（USD） | 2025财年 |
|---|---|
| 研究与开发 | 1.53亿 USD |
| 销售、一般及管理费用 | 4875万 USD |
| 营业费用 | 2.02亿 USD |
| 利息收入 | 685万 USD |
| 折旧和摊销 | 584.7万 USD |
| 营业利润 | −2.02亿 USD |
| 净利润 | −1.92亿 USD |
公司数据更新于 2026年10月8日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$38.50
上涨空间 180.11%报告持有此股票敞口的交易所交易基金。
iShares Russell 2000 ETFIWM1032.81万0.01%785.63亿 USD0.19%US$276.02-0.60%
iShares Russell 2000 Growth ETFIWO219.73万0.02%142.49亿 USD0.24%US$351.83-1.00%
Vanguard Morningstar Total Stock Market ETFVTI190.56万0.00%2.3万亿 USD0.03%US$380.16-0.23%
Schwab U.S. Small-Cap ETFSCHA181.2万0.01%216.99亿 USD0.03%US$32.44-0.52%
Vanguard Extended Market ETFVXF67.04万0.00%954亿 USD0.05%US$232.18-0.56%
Goldman Sachs Small Cap Equity ETFGSC50.73万0.18%2.81亿 USD0.80%US$61.25-1.11%
Vanguard Russell 2000 ETFVTWO31.97万0.00%180亿 USD0.06%US$111.43-0.70%
Fidelity Nasdaq Composite Index ETFONEQ28.22万—109.4亿 USD0.21%US$107.97-0.44%iShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Morningstar Total Stock Market ETFVTISchwab U.S. Small-Cap ETFSCHAVanguard Extended Market ETFVXFGoldman Sachs Small Cap Equity ETFGSCVanguard Russell 2000 ETFVTWOFidelity Nasdaq Composite Index ETFONEQAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
